Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia

International Journal of Antimicrobial Agents

Volumn 39, Issue 4, 2012, Pages 321-325

  Biedenbach, Douglas J ^a   Farrell, David J ^a   Flamm, Robert K ^a   Liverman, Lisa C ^b   McIntyre, Gail ^b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b Furiex Pharmaceuticals Inc   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Community acquired bacterial pneumonia; Fluoroquinolones; JNJ Q2; Pathogens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; JNJ Q 2; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; COMMUNICABLE DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GEOGRAPHY; HAEMOPHILUS INFLUENZAE; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; OFLOXACIN; PNEUMONIA, BACTERIAL; QUINOLINES; STREPTOCOCCUS PNEUMONIAE;

EID: 84862801898     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.11.016     Document Type: Article

References (26)

1. Frei CR, Labreche MJ, Attridge RT. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use. Drugs 2011;71: 757-70.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl. 2):S27-72. (Pubitemid 46290553)
3. Wispelwey B, Schafer KR. Fluoroquinolones in the management of community-acquired pneumonia in primary care. Expert Rev Anti Infect Ther 2010;8: 1259-71.
4. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;46:285-9. (Pubitemid 37025766)
5. Sahm DF, Brown NP, Thornsberry C, Jones ME. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. Postgrad Med 2008;120:16-24.
6. Jones RN, Jacobs MR, Sader HS. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Antimicrob Agents 2010;36:197-204.
7. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-64. (Pubitemid 351269151)
8. Moellering Jr RC. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother 2010;65(Suppl. 4):iv3-8.
9. Jones RN, Fritsche TR, Sader HS. Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2005;52:129-33. (Pubitemid 40826939)
10. Blumberg HM, Rimland D, Carroll DJ, Terry P, Wachsmuth IK. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J Infect Dis 1991;163:1279-85.
11. Biedenbach DJ, Farrell DJ, Mendes RE, Ross JE, Jones RN. Stability of linezolid activity in an era of mobile oxazolidinone resistance determinants: results from the 2009 Zyvox® Annual Appraisal of Potency and Spectrum program. Diagn Microbiol Infect Dis 2010;68:459-67.
12. Pletz MW, van der Linden M, von Baum H, Duesberg CB, Klugman KP, Welte T. Low prevalence of fluoroquinolone resistant strains and resistance precursor strains in Streptococcus pneumoniae from patients with community-acquired pneumonia despite high fluoroquinolone usage. Int J Med Microbiol 2011;301:53-7.
13. Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents 2009;34:82-5.
14. Biedenbach DJ, Jones RN. Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 2003;46:55-61. (Pubitemid 36556022)
15. DiPersio JR, Jones RN, Barrett T, Doern GV, Pfaller MA. Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998). Diagn Microbiol Infect Dis 1998;32:131-5. (Pubitemid 28526456)
16. Yokota S, Ohkoshi Y, Sato K, Fujii N. Emergence of fluoroquinolone- resistant Haemophilus influenzae strains among elderly patients but not among children. J Clin Microbiol 2008;46:361-5.
17. Jones RN, Fritsche TR, Sader HS. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates. Antimicrob Agents Chemother 2008;52:3763-75.
18. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, et al. In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother 2010;54:1955-64.
19. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 2006;50:2261-4.
20. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert DN. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. Clin Infect Dis 2008;47(Suppl. 3):S249-65.
21. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN. JNJ-Q2: a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains. Antimicrob Agents Chemother 2011;55:3631-4.
22. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2009.
23. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-8. (Pubitemid 46183361)
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. Document M100-S21. Wayne, PA: CLSI; 2011.
25. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011. EUCAST; 2011. http://www.eucast.org/clinical breakpoints/ [accessed 5 January 2012].
26. Ramirez JA, Anzueto AR. Changing needs of community-acquired pneumonia. J Antimicrob Chemother 2011;66(Suppl. 3):iii3-9.